Evidence map›Paper›PMID 33973276›Full record

ArticleEuropean journal of haematology2021

Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.

Krithika Shanmugasundaram, Subir Goyal, Jeffery Switchenko, Oscar Calzada, Michael C Churnetski, Bhaskar Kolla, Veronika Bachanova, James N Gerson, Stefan K Barta, Max J Gordon and 21 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 15 institutions in 2 countries.

Krithika ShanmugasundaramNational Institutes of Health, National Cancer Institute, Bethesda, MD, US.ORCID https://orcid.org/0000-0003-1006-4609
Subir GoyalWinship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA, US.
Jeffery SwitchenkoWinship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA, US.
Oscar CalzadaDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University Hospital, Atlanta, GA, US.
Michael C ChurnetskiDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University Hospital, Atlanta, GA, US.
Bhaskar KollaDivision of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN, US.
Veronika BachanovaDivision of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN, US.
James N GersonHematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, US.
Stefan K BartaHematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, US.
Max J GordonKnight Cancer Institute, Oregon Health and Science University, Portland, OR, US.
Alexey V DanilovKnight Cancer Institute, Oregon Health and Science University, Portland, OR, US.
Natalie S GroverLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, US.
Stephanie MathewsLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, US.
Madelyn BurkartDivision of Hematology, Northwestern University, Chicago, IL, US.
Reem KarmaliDivision of Hematology, Northwestern University, Chicago, IL, US.
Yazeed SawalhaDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, US.ORCID https://orcid.org/0000-0001-6355-3671
Brian T HillDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, US.
Nilanjan GhoshLevine Cancer Institute, Charlotte, NC, US.
Steven I ParkLevine Cancer Institute, Charlotte, NC, US.
Narendranath EpperlaDivision of Hematology, The Ohio State University Cancer Center, Columbus, OH, US.
David A BondDivision of Hematology, The Ohio State University Cancer Center, Columbus, OH, US.
Talha BadarMayo Clinic, Jacksonville, FL, US.
Kristie A BlumDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University Hospital, Atlanta, GA, US.
Mehdi HamadaniDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, US.
Timothy S FenskeDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, US.
Mary MalecekSiteman Cancer Center, Washington University, St. Louis, MO, US.
Brad S KahlSiteman Cancer Center, Washington University, St. Louis, MO, US.
Peter MartinWeill Cornell Medicine, New York, NY, US.
Jin GuoDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
Christopher R FlowersDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
Jonathon B CohenDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University Hospital, Atlanta, GA, US.
Emory University · USCleveland Clinic · USHospital of the University of Pennsylvania · USLevine Cancer Institute · USMayo Clinic · USMedical College of Wisconsin · USNorthwestern University · USOregon Health & Science University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · USWashington University in St. Louis · USCornell University · USNational Institutes of Health · USThe Ohio State University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
TRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8M
Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory UniversityNCI Grant P30CA138292NCI NIH HHS P30 CA138292NCI NIH HHS T32 CA009666
6 · The paper itself

Abstract

introductionWhile most patients with mantle cell lymphoma (MCL) receive therapy shortly after diagnosis, a subset of patients with indolent-behaving disease can safely defer treatment. In this subgroup, we evaluated the importance of treatment intensity in patients with MCL who defer initial therapy.

methodsOut of 1134 patients with MCL from 12 academic centers, we analyzed 219 patients who initiated therapy at least 90 days after diagnosis. Patients who received induction with high-dose cytarabine and/or autologous stem cell transplantation (ASCT) in first remission were considered to have received intensive therapy (n = 88) while all other approaches were non-intensive (n = 131).

resultsThere was no difference in progression-free (PFS; P = .224) or overall survival (OS; P = .167) in deferred patients who received non-intensive vs. intensive therapy. Additionally, univariate and multivariate Cox proportional hazards models were performed for PFS and OS. Treatment at an academic center (HR 0.43, P = .015) was associated with improved OS in both univariate and multivariate models, while intensity of treatment was not associated with improved OS in either model.

conclusionsThese results indicate that intensified initial treatment is not associated with improved survival after deferring initial therapy, although prospective studies are needed to determine which of these patients with MCL may benefit from intensive therapy.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideCytarabineDexamethasoneDisease-Free SurvivalDoxorubicinFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Mantle-CellMaleMiddle AgedProportional Hazards ModelsRemission InductionRetrospective StudiesCyclophosphamideCytarabineDexamethasoneDoxorubicinVincristinedeferredintensive therapymantle cell lymphomatime to treatment

Identifiers

PMID33973276
PMCPMC8338766
OpenAlexW3160622871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.